Prognostic Factors and Biomarkers of Responses to Immune Checkpoint Inhibitors in Lung Cancer
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Prognostic Factors and Biomarkers of Responses to Immune Checkpoint Inhibitors in Lung Cancer
Authors
Keywords
-
Journal
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
Volume 20, Issue 19, Pages 4931
Publisher
MDPI AG
Online
2019-10-07
DOI
10.3390/ijms20194931
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Assessment of Blood Tumor Mutational Burden as a Potential Biomarker for Immunotherapy in Patients With Non–Small Cell Lung Cancer With Use of a Next-Generation Sequencing Cancer Gene Panel
- (2019) Zhijie Wang et al. JAMA Oncology
- Atezolizumab plus platinum-based regimen and bevacizumab: is it time to consider immunotherapy in a concurrent approach for lung cancer?
- (2019) Andrea Bianco et al. Translational Cancer Research
- Endoscopic central airway recanalization to enable first line pembrolizumab treatment in a PD-L1 strongly positive non-small cell lung cancer: a case report
- (2019) Alfonso Fiorelli et al. Journal of Cardiothoracic Surgery
- Immune Checkpoint Blockade for Advanced NSCLC: A New Landscape for Elderly Patients
- (2019) Fabio Perrotta et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Genomic characterization of lung tumors and metastatic (Met) sites in advanced (Adv) NSCLC.
- (2019) Melinda D Willard et al. JOURNAL OF CLINICAL ONCOLOGY
- Association of STK11/LKB1 genomic alterations with lack of benefit from the addition of pembrolizumab to platinum doublet chemotherapy in non-squamous non-small cell lung cancer.
- (2019) Ferdinandos Skoulidis et al. JOURNAL OF CLINICAL ONCOLOGY
- Tumor-induced escape mechanisms and their association with resistance to checkpoint inhibitor therapy
- (2019) Michael Friedrich et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors: Guideline From the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology
- (2018) Neal I. Lindeman et al. ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE
- PD-L1 and Emerging Biomarkers in Immune Checkpoint Blockade Therapy
- (2018) Tricia R. Cottrell et al. CANCER JOURNAL
- Targeting immune checkpoints in non small cell lung cancer
- (2018) Andrea Bianco et al. CURRENT OPINION IN PHARMACOLOGY
- NCCN Guidelines Insights: Non–Small Cell Lung Cancer, Version 5.2018
- (2018) David S. Ettinger et al. Journal of the National Comprehensive Cancer Network
- PD-L1 Immunohistochemistry Comparability Study in Real-Life Clinical Samples: Results of Blueprint Phase 2 Project
- (2018) Ming Sound Tsao et al. Journal of Thoracic Oncology
- Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study
- (2018) Marina Chiara Garassino et al. LANCET ONCOLOGY
- The role of tumor-infiltrating lymphocytes (TILs) as a predictive biomarker of response to anti-PD1 therapy in patients with metastatic non-small cell lung cancer or metastatic melanoma
- (2018) Anton Uryvaev et al. MEDICAL ONCOLOGY
- Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC
- (2018) Mark A. Socinski et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden
- (2018) Matthew D. Hellmann et al. NEW ENGLAND JOURNAL OF MEDICINE
- The commensal microbiome is associated with anti–PD-1 efficacy in metastatic melanoma patients
- (2018) Vyara Matson et al. SCIENCE
- STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS -Mutant Lung Adenocarcinoma
- (2018) Ferdinandos Skoulidis et al. Cancer Discovery
- Oncogene-addicted non-small cell lung cancer and immunotherapy
- (2018) Georgios Tsakonas et al. Journal of Thoracic Disease
- The Role of Indoleamine-2,3-Dioxygenase in Cancer Development, Diagnostics, and Therapy
- (2018) Lilla Hornyák et al. Frontiers in Immunology
- OUP accepted manuscript
- (2018) ANNALS OF ONCOLOGY
- Increased Tim-3+ T cells in PBMCs during nivolumab therapy correlate with responses and prognosis of advanced esophageal squamous cell carcinoma patients
- (2018) Ryo Kato et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- A comprehensive review on the role of co-signaling receptors and Treg homeostasis in autoimmunity and tumor immunity
- (2018) Prabhakaran Kumar et al. JOURNAL OF AUTOIMMUNITY
- High-dimensional single cell analysis identifies stem-like cytotoxic CD8+T cells infiltrating human tumors
- (2018) Jolanda Brummelman et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Targeting the IDO1 pathway in cancer: from bench to bedside
- (2018) Ming Liu et al. Journal of Hematology & Oncology
- Can IDO activity predict primary resistance to anti-PD-1 treatment in NSCLC?
- (2018) Andrea Botticelli et al. Journal of Translational Medicine
- Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab
- (2018) David R. Gandara et al. NATURE MEDICINE
- Pembrolizumab plus Chemotherapy in Lung Cancer
- (2018) NEW ENGLAND JOURNAL OF MEDICINE
- Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer
- (2018) Luis Paz-Ares et al. NEW ENGLAND JOURNAL OF MEDICINE
- Role of Immunotherapy for Oncogene-Driven Non-Small Cell Lung Cancer
- (2018) Yosuke Miura et al. Cancers
- Contribution of regulatory T cells to cancer: A review
- (2018) Masoud Najafi et al. JOURNAL OF CELLULAR PHYSIOLOGY
- T lymphocyte subsets in cancer immunity: Friends or foes
- (2018) Dounia Chraa et al. JOURNAL OF LEUKOCYTE BIOLOGY
- TIM-3, a promising target for cancer immunotherapy
- (2018) Yayi He et al. OncoTargets and Therapy
- The rationale of indoleamine 2,3-dioxygenase inhibition for cancer therapy
- (2017) Lieve Brochez et al. EUROPEAN JOURNAL OF CANCER
- Systemic Therapy for Stage IV Non–Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update
- (2017) Nasser Hanna et al. JOURNAL OF CLINICAL ONCOLOGY
- PD-L1 Immunohistochemistry Assays for Lung Cancer: Results from Phase 1 of the Blueprint PD-L1 IHC Assay Comparison Project
- (2017) Fred R. Hirsch et al. Journal of Thoracic Oncology
- LKB1/STK11 mutations in non-small cell lung cancer patients: Descriptive analysis and prognostic value
- (2017) Francesco Facchinetti et al. LUNG CANCER
- Patient HLA class I genotype influences cancer response to checkpoint blockade immunotherapy
- (2017) Diego Chowell et al. SCIENCE
- Gut microbiome modulates response to anti–PD-1 immunotherapy in melanoma patients
- (2017) V. Gopalakrishnan et al. SCIENCE
- The efficacy of anti-PD-1/PD-L1 therapy and its comparison with EGFR-TKIs for advanced non-small-cell lung cancer
- (2017) Zhixin Sheng et al. Oncotarget
- Role of tumor microenvironment in tumorigenesis
- (2017) Maonan Wang et al. Journal of Cancer
- Nivolumab as Programmed Death-1 (PD-1) Inhibitor for Targeted Immunotherapy in Tumor
- (2017) Liting Guo et al. Journal of Cancer
- EGFR mutation correlates with uninflamed phenotype and weak immunogenicity, causing impaired response to PD-1 blockade in non-small cell lung cancer
- (2017) Zhong-Yi Dong et al. OncoImmunology
- Non–Small Cell Lung Cancer
- (2017) David S. Ettinger et al. Journal of the National Comprehensive Cancer Network
- Molecular mechanism of PD-1/PD-L1 blockade via anti-PD-L1 antibodies atezolizumab and durvalumab
- (2017) Hyun Tae Lee et al. Scientific Reports
- Phase I, safety, tolerability and preliminary efficacy study of tremelimumab (Trem) in combination with gefitinib (Gef) in EGFR-mutant (EGFR-mut) NSCLC (GEFTREM)
- (2016) D. Planchard et al. ANNALS OF ONCOLOGY
- Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer
- (2016) Martin Reck et al. NEW ENGLAND JOURNAL OF MEDICINE
- FDA Approval Summary: Pembrolizumab for the Treatment of Patients With Metastatic Non-Small Cell Lung Cancer Whose Tumors Express Programmed Death-Ligand 1
- (2016) Joohee Sul et al. ONCOLOGIST
- Preferential expansion of pro-inflammatory Tregs in human non-small cell lung cancer
- (2015) Joseph D. Phillips et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Classifying Cancers Based on T-cell Infiltration and PD-L1
- (2015) Michele W.L. Teng et al. CANCER RESEARCH
- CD8+CD103+Tumor–Infiltrating Lymphocytes Are Tumor-Specific Tissue-Resident Memory T Cells and a Prognostic Factor for Survival in Lung Cancer Patients
- (2015) Fayçal Djenidi et al. JOURNAL OF IMMUNOLOGY
- Objective Measurement and Clinical Significance of TILs in Non–Small Cell Lung Cancer
- (2015) Kurt A. Schalper et al. JNCI-Journal of the National Cancer Institute
- Neoantigens in cancer immunotherapy
- (2015) T. N. Schumacher et al. SCIENCE
- Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer
- (2015) N. A. Rizvi et al. SCIENCE
- Different prognostic impact of STK11 mutations in non-squamous non-small-cell lung cancer
- (2015) Nicolas Pécuchet et al. Oncotarget
- Objective Measurement and Clinical Significance of TILs in Non–Small Cell Lung Cancer
- (2015) Kurt A. Schalper et al. JNCI-Journal of the National Cancer Institute
- Immune and Inflammatory Cell Composition of Human Lung Cancer Stroma
- (2015) G-Andre Banat et al. PLoS One
- Safety and Response With Nivolumab (Anti-PD-1; BMS-936558, ONO-4538) Plus Erlotinib in Patients (Pts) With Epidermal Growth Factor Receptor Mutant (EGFR MT) Advanced Non-Small Cell Lung Cancer (NSCLC)
- (2014) S. Gettinger et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- Accessories to the Crime: Functions of Cells Recruited to the Tumor Microenvironment
- (2012) Douglas Hanahan et al. CANCER CELL
- Recruitment of Grb2 and SHIP1 by the ITT-like motif of TIGIT suppresses granule polarization and cytotoxicity of NK cells
- (2012) S Liu et al. CELL DEATH AND DIFFERENTIATION
- Dual function of CTLA-4 in regulatory T cells and conventional T cells to prevent multiorgan autoimmunity
- (2010) N. Jain et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- CD4+regulatory T cells require CTLA-4 for the maintenance of systemic tolerance
- (2009) Randall H. Friedline et al. JOURNAL OF EXPERIMENTAL MEDICINE
- PD-L1 regulates the development, maintenance, and function of induced regulatory T cells
- (2009) Loise M. Francisco et al. JOURNAL OF EXPERIMENTAL MEDICINE
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now